Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Urothelkarzinoms

Translated title of the contribution: Role of immunotherapy in perioperative treatment of localized muscle-invasive urothelial cancer

J. Lewerich, S. C. Schmid, J. E. Gschwend, M. Retz

Research output: Contribution to journalReview articlepeer-review


Background: Immune checkpoint inhibitors are the standard of care in the first-line and second-line treatment of metastatic and locally advanced urothelial cancer. The use of immunotherapy in perioperative treatment is a new focus in the uro-oncological landscape. Current studies are investigating immune checkpoint inhibitors as monotherapy and in combination with chemotherapy or irradiation in the perioperative setting. Objective: Overview of the currently published data, overview of new study concepts and an outlook on future developments in perioperative immunotherapy. Conclusion: Neoadjuvant monotherapy with immune checkpoint inhibitors has failed to show sufficient response rates in muscle-invasive bladder cancer. In contrast, higher response rates have been observed for combinations of immunotherapy and established chemotherapy regimens, so that current phase III trials are now investigating this approach. Among others, sandwich regimens consisting of neoadjuvant immunochemotherapy and adjuvant immunotherapy following radical cystectomy are currently being investigated. Immune checkpoint inhibitors were investigated as adjuvant treatment in patients with high risk of recurrence in muscle-invasive urothelial cancer following radical resection. In this group a significant advantage with respect to disease-free survival (DFS) was observed for adjuvant immunotherapy with nivolumab. The effect was particularly pronounced in patients with a tumor status positive for programmed cell death 1 ligand 1 (PD-L1), so that the European Medicines Agency (EMA) has approved adjuvant immunotherapy with nivolumab for this subgroup as a new uro-oncological treatment indication.

Translated title of the contributionRole of immunotherapy in perioperative treatment of localized muscle-invasive urothelial cancer
Original languageGerman
Pages (from-to)782-791
Number of pages10
Issue number9
StatePublished - Sep 2022
Externally publishedYes


Dive into the research topics of 'Role of immunotherapy in perioperative treatment of localized muscle-invasive urothelial cancer'. Together they form a unique fingerprint.

Cite this